Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sho Tashiro"'
Autor:
Moeko Tsutsuura, Hiromu Moriyama, Nana Kojima, Yuki Mizukami, Sho Tashiro, Sumika Osa, Yuki Enoki, Kazuaki Taguchi, Kazutaka Oda, Satoshi Fujii, Yoshiko Takahashi, Yukihiro Hamada, Toshimi Kimura, Yoshio Takesue, Kazuaki Matsumoto
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background This systematic review and meta-analysis explored the relationship between vancomycin (VCM) monitoring strategies and VCM effectiveness and safety. Methods We conducted our analysis using the MEDLINE, Web of Sciences, and Cochrane
Externí odkaz:
https://doaj.org/article/8ed0fa5611b2497f8e6f1a95a9efb213
Autor:
Masaru Samura, Yuki Kitahiro, Sho Tashiro, Hiromu Moriyama, Yuna Hamamura, Isamu Takahata, Rina Kawabe, Yuki Enoki, Kazuaki Taguchi, Yoshio Takesue, Kazuaki Matsumoto
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 714 (2022)
This systematic review and meta-analysis compares the efficacy of daptomycin and vancomycin in adult patients with bacteremia by methicillin-resistant Staphylococcus aureus (MRSA) with vancomycin minimum inhibitory concentration (MIC) > 1 µg/mL. We
Externí odkaz:
https://doaj.org/article/9a513a8c0bcf410b8b495071f614ff8d
Autor:
Sho Tashiro, Takayuki Mihara, Moe Sasaki, Chiaki Shimamura, Rina Shimamura, Shiho Suzuki, Maiko Yoshikawa, Tatsuki Hasegawa, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto, Hiroki Ohge, Hiromichi Suzuki, Atsushi Nakamura, Nobuaki Mori, Yoshitomo Morinaga, Yuka Yamagishi, Sadako Yoshizawa, Katsunori Yanagihara, Hiroshige Mikamo, Hiroyuki Kunishima
Publikováno v:
Journal of Infection and Chemotherapy. 28:1536-1545
Fidaxomicin (FDX) has received considerable attention as a novel therapeutic alternative agent to vancomycin (VCM) for Clostridioides difficile infection (CDI). However, the superiority and efficacy profile of FDX are not sufficiently determined by h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::060653f36c1f9b4253fe8a27bbf67f70
https://doi.org/10.1016/j.jiac.2022.08.008
https://doi.org/10.1016/j.jiac.2022.08.008
Publikováno v:
Pharmaceutical Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02ef7481251375842505aa1d0749dad0
https://doi.org/10.1007/s11095-023-03537-6
https://doi.org/10.1007/s11095-023-03537-6
Autor:
Sho Tashiro, Takayuki Mihara, Rikiya Okawa, Yoko Tanaka, Masaru Samura, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto, Yuka Yamagishi
Publikováno v:
European Journal of Pediatrics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3bfbca49bf7bddc839de3f898d67288
https://doi.org/10.1007/s00431-023-04944-y
https://doi.org/10.1007/s00431-023-04944-y
Autor:
Nana Kojima, Yuki Igarashi, Tomonori Nakamura, Yuta Yokoyama, Wataru Takemura, Marina Hayashi, Yuki Mizukami, Kazuaki Taguchi, Sho Tashiro, Kazuaki Matsumoto, Yuki Enoki, Xiaoxi Liu, Takumi Morita
Publikováno v:
Pharmaceutical Research. 38:1839-1846
PURPOSE Cefmetazole (CMZ) has received attention as a pharmaceutical intervention for extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) infections. This study aimed to investigate the pharmacokinetics/pharmacodynamics (PK/PD) char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed02cff9d2e1c86243b7b533892b8df
https://doi.org/10.1007/s11095-021-03140-7
https://doi.org/10.1007/s11095-021-03140-7
Autor:
Tatsuki Hasegawa, Sho Tashiro, Takayuki Mihara, Junya Kon, Kazuki Sakurai, Yoko Tanaka, Takumi Morita, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto, Kazuhiko Nakajima, Yoshio Takesue
Publikováno v:
BJS Open. 6
Background A combination of chlorhexidine gluconate and alcohol (CHG–alcohol) is recommended for surgical skin preparation to prevent surgical site infection (SSI). Although more than 1 per cent CHG–alcohol is recommended to prevent catheter-rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df800f7d1f8ab877380db6d9f43c860
https://doi.org/10.1093/bjsopen/zrac111
https://doi.org/10.1093/bjsopen/zrac111
Publikováno v:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
The pharmacokinetics/pharmacodynamics (PK/PD) characteristics of fidaxomicin (FDX) and vancomycin (VCM) against Clostridioides difficile infection (CDI) are yet to be elucidated because of the lack of an established PK/PD analysis method for intestin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea46c60fa01e8efcfac0801989539ea
https://pubmed.ncbi.nlm.nih.gov/36574949
https://pubmed.ncbi.nlm.nih.gov/36574949
Autor:
Xiaoxi Liu, Sho Tashiro, Yuki Igarashi, Wataru Takemura, Nana Kojima, Takumi Morita, Marina Hayashi, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto
Publikováno v:
Pharmaceutical research.
Vancomycin-resistant enterococci (VRE) have recently become a major cause of nosocomial infections and a global public health concern. Tedizolid exhibits powerful antibacterial activity against VRE in vitro, but its pharmacokinetic/pharmacodynamic (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed46bb9eb5c43571193e89df3caaa1e0
https://pubmed.ncbi.nlm.nih.gov/36329373
https://pubmed.ncbi.nlm.nih.gov/36329373
Autor:
Kazuaki Matsumoto, Masaru Samura, Sho Tashiro, Shino Shishido, Reika Saiki, Wataru Takemura, Kana Misawa, Xiaoxi Liu, Yuki Enoki, Kazuaki Taguchi
Publikováno v:
Biologicalpharmaceutical bulletin. 45(7)
The target therapeutic ranges of vancomycin, teicoplanin, and arbekacin have been determined, and therapeutic drug monitoring (TDM) is performed in clinical practice. However, TDM is not obligatory for daptomycin, linezolid, or tedizolid. In this stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c8db2aade297a3aef789fb035c5aaad
https://pubmed.ncbi.nlm.nih.gov/35786589
https://pubmed.ncbi.nlm.nih.gov/35786589